ATEA PHARMACEUTICALS INC (AVIR) Stock Overview
NASDAQ:AVIR - US04683R1068 - Common Stock
AVIR Key Statistics, Chart & Performance
The current stock price of AVIR is 3.6 USD. In the past month the price decreased by -1.91%. In the past year, price decreased by -6.49%.
AVIR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.46 | 694.86B | ||
| JNJ | JOHNSON & JOHNSON | 17.68 | 425.77B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.47 | 250.79B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.34 | 245.64B | ||
| MRK | MERCK & CO. INC. | 10.92 | 209.99B | ||
| PFE | PFIZER INC | 7.4 | 142.54B | ||
| SNY | SANOFI-ADR | 11.34 | 122.22B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.08 | 96.95B | ||
| GSK | GSK PLC-SPON ADR | 8.83 | 80.45B | ||
| ZTS | ZOETIS INC | 24.98 | 68.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.53 | 46.93B |
Related stock screener links
About AVIR
Company Profile
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The firm has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
Company Info
ATEA PHARMACEUTICALS INC
225 Franklin Street, Suite 2100
Boston MASSACHUSETTS 02110 US
CEO: Jean-Pierre Sommadossi
Employees: 56
Phone: 18572048109
ATEA PHARMACEUTICALS INC / AVIR FAQ
What is the stock price of ATEA PHARMACEUTICALS INC today?
The current stock price of AVIR is 3.6 USD. The price decreased by -1.37% in the last trading session.
What is the ticker symbol for ATEA PHARMACEUTICALS INC stock?
The exchange symbol of ATEA PHARMACEUTICALS INC is AVIR and it is listed on the Nasdaq exchange.
On which exchange is AVIR stock listed?
AVIR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATEA PHARMACEUTICALS INC stock?
8 analysts have analysed AVIR and the average price target is 6.12 USD. This implies a price increase of 70% is expected in the next year compared to the current price of 3.6. Check the ATEA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATEA PHARMACEUTICALS INC worth?
ATEA PHARMACEUTICALS INC (AVIR) has a market capitalization of 285.70M USD. This makes AVIR a Micro Cap stock.
How many employees does ATEA PHARMACEUTICALS INC have?
ATEA PHARMACEUTICALS INC (AVIR) currently has 56 employees.
What are the support and resistance levels for ATEA PHARMACEUTICALS INC (AVIR) stock?
ATEA PHARMACEUTICALS INC (AVIR) has a support level at 3.56 and a resistance level at 3.62. Check the full technical report for a detailed analysis of AVIR support and resistance levels.
Should I buy ATEA PHARMACEUTICALS INC (AVIR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AVIR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AVIR, evaluating the profitability, health, valuation and growth aspects
- ATEA PHARMACEUTICALS INC (AVIR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATEA PHARMACEUTICALS INC (AVIR) Sales and EPS estimates to see what analysts future expectations are.
- ATEA PHARMACEUTICALS INC (AVIR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATEA PHARMACEUTICALS INC (AVIR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATEA PHARMACEUTICALS INC (AVIR) Stock Chart to make your own analysis
- ATEA PHARMACEUTICALS INC (AVIR) Latest news and press-releases to stay up to date.
Does ATEA PHARMACEUTICALS INC (AVIR) stock pay dividends?
AVIR does not pay a dividend.
When does ATEA PHARMACEUTICALS INC (AVIR) report earnings?
ATEA PHARMACEUTICALS INC (AVIR) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of ATEA PHARMACEUTICALS INC (AVIR)?
ATEA PHARMACEUTICALS INC (AVIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
What is the Short Interest ratio of ATEA PHARMACEUTICALS INC (AVIR) stock?
The outstanding short interest for ATEA PHARMACEUTICALS INC (AVIR) is 5.91% of its float. Check the ownership tab for more information on the AVIR short interest.
AVIR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AVIR. When comparing the yearly performance of all stocks, AVIR turns out to be only a medium performer in the overall market: it outperformed 57.11% of all stocks.
AVIR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVIR. No worries on liquidiy or solvency for AVIR as it has an excellent financial health rating, but there are worries on the profitability.
AVIR Financial Highlights
Over the last trailing twelve months AVIR reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS increased by 23.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.76% | ||
| ROE | -37.35% | ||
| Debt/Equity | 0 |
AVIR Forecast & Estimates
8 analysts have analysed AVIR and the average price target is 6.12 USD. This implies a price increase of 70% is expected in the next year compared to the current price of 3.6.